Skip to main content
Smart Investors Daily
BIOLASE, Inc. logo

NASDAQ · BIOL

BIOLASE, Inc.

Healthcare · Medical - Devices

$0.02

Up+$0.00 (+27.39%)

Updated Aug 14, 2026, 8:19 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
731.94K
P/E ratio
-0.17
Dividend yield
0.00%
52-week range
— – —
Volume
2.67M
Avg. volume
212.69K

Price performance

BIOL price history

1M range · 0 trading sessions · Daily adjusted prices

BIOL does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest BIOL news

The latest Smart Investors Daily articles mentioning BIOL.

BIOL research

Overview

Company profile and research snapshot.

Company profile

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
BIOL recent ratings
DateFirmRatingTarget
Oct 2, 2024BenchmarkSpeculative Buy
Sep 3, 2024Ascendiant CapitalBuy
Aug 12, 2024BenchmarkSpeculative Buy
May 14, 2024BenchmarkSpeculative Buy
Apr 1, 2024Ascendiant CapitalBuy
Open full forecast

News briefing

No generated briefing is available yet.

prnewswire.com · Nov 25, 2025

BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025

NEW YORK , Nov. 25, 2025 /PRNewswire/ -- BIOLASE, the global leader in dental lasers, announced its participation in the 2025 Greater New York Dental Meeting (GNYDM), taking place November 28–December 3 in New York City. As part of the program, BIOLASE will host a featured lecture led by Philip Kang, DDS, focused on advancing laser solutions for periodontal and implant health.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.